403. Can BioTech Extend Life to 150 Years? Gene Editing, and Investing in the Future of Life Sciences (Risa Stack)

Investor Stories 386: Disruptive Forces (Yunger, Chau, Whitmire)

467. Lessons from Jobs, Musk, Case, and Armstrong – What It Takes to Transform Industries and Build Trillion-Dollar Companies (Barry Schuler)

Investor Stories 385: Key Advice (Inkinen, Roizen, Boduch)

466. Investing in xAI, Wiz, and Flexport; Masayoshi Son’s Superpower; How Elon Will Win the LLM War; and Whether AI Is an Extinction-Level Event for SaaS (Kevin Jiang)

Investor Stories 384: Visionary Founders (Upham, Patil, Chase)

465. The Villain Test, Lessons from an OG at Sequoia, Spotting Superstars at Seed, Mastering Follow-on, and the Future of Consumer Tech (Craig Shapiro)

Investor Stories 383: Best LP Question (Droesch, Inkinen, Roizen)

Investor Stories 382: Lessons Learned (von Tobel, Felesky, Patil)

OMR #460 mit Investor Christian Angermayer

Covid Vaccine Pioneer Bob Langer: Turning Science Into Billlion Dollar Ideas

DNA als Plattform der Zukunft

Trevor Martin (Mammoth Biosciences) and Ursheet Parikh (Mayfield) - Building Biotech to Last

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

CRISPR/Cas9 mit Myopax

Startup Insider Daily • Tesla-Hack • Insolvenzantragspflicht • Ripple • Basecamp-Exodus • CRISPR • Netflix

E42: China's tech crackdown, CRISPR breakthrough, practical climate change solutions & more